阿石創(300706.SZ):擬以2654.329萬元收購常州蘇晶15.6137%的股權
格隆匯12月10日丨阿石創(300706.SZ)公佈,公司於2021年12月10日召開第三屆董事會第八次會議,審議通過了《關於子公司擬收購常州蘇晶電子材料有限公司15.6137%股權的議案》,為進一步增強公司對控股子公司的管控力度,提高經營決策效率,增強公司持續盈利能力,公司擬授權全資子公司福建頂創控股有限公司(“頂創控股”)以自有資金2654.329萬元收購平潭興證鑫澤股權投資合夥企業(有限合夥)(“興證鑫澤”)持有的常州蘇晶電子材料有限公司(“常州蘇晶”)15.6137%的股權,此次交易完成後,頂創控股持有常州蘇晶52.8748%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.